Assessing causal mechanistic interactions: a peril ratio index of synergy based on multiplicativity

Wen-Chung Lee1

  • 1Research Center for Genes, Environment and Human Health, College of Public Health, National Taiwan University, Taipei, Taiwan. wenchung@ntu.edu.tw

Plos One
|July 5, 2013
PubMed

Insights

This study introduces a new metric, the peril ratio index of synergy based on multiplicativity (PRISM), to better assess mechanistic interactions in epidemiology. PRISM identifies genuine causal synergisms missed by traditional statistical methods.

Area of Science:

  • Epidemiology
  • Biostatistics
  • Causal Inference

Background:

  • Traditional epidemiological interaction assessment relies on statistical convenience metrics like risk-ratios.
  • These methods often lead to misinterpretation of statistical significance as mechanistic interaction.
  • A novel metric system for risk, 'peril,' is introduced as an alternative.

Purpose of the Study:

  • To propose a new index, the peril ratio index of synergy based on multiplicativity (PRISM), for assessing mechanistic interactions.
  • To demonstrate PRISM's ability to detect synergisms in the sufficient cause sense.
  • To compare PRISM's sensitivity with existing interaction indices.

Main Methods:

  • Adoption of 'peril' as an alternative risk metric.
  • Development of PRISM based on the multiplicativity of peril ratios.
  • Assumption of no redundancy for assessing causal co-actions.

Main Results:

  • PRISM can identify causal mechanistic interactions (synergisms) under the no redundancy assumption.
  • PRISM exhibits a less stringent threshold for synergy detection compared to the relative excess risk due to interaction.
  • The new criterion reveals bona fide synergisms in situations previously deemed non-interactive.

Conclusions:

  • PRISM offers a more accurate approach to identifying genuine epidemiological interactions.
  • The metric provides a valuable tool for understanding causal co-actions in disease etiology.
  • Epidemiological research can benefit from employing PRISM for more precise interaction assessment.

Related Concept Videos

Agonism and Antagonism: Quantification01:14

Agonism and Antagonism: Quantification

When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Odds Ratio01:09

Odds Ratio

The odds ratio (OR) is a statistical measure used extensively in epidemiology and research to quantify the strength of association between exposure and outcome across different groups. Unlike relative risk, which compares the probabilities of an event occurring, the odds ratio compares the odds of an event occurring in the exposed group to the odds of it occurring in the unexposed group. The odds, in this context, are calculated as the probability of the event happening divided by the...
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Relative Risk01:12

Relative Risk

Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...